PMV Pharmaceuticals Management
Management criteria checks 3/4
PMV Pharmaceuticals' CEO is David Mack, appointed in Jul 2013, has a tenure of 11.42 years. total yearly compensation is $2.21M, comprised of 26.5% salary and 73.5% bonuses, including company stock and options. directly owns 1.25% of the company’s shares, worth $953.69K. The average tenure of the management team and the board of directors is 3.8 years and 3.8 years respectively.
Key information
David Mack
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 26.5% |
| CEO tenure | 11.4yrs |
| CEO ownership | 1.3% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Aug 04
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25PMV Pharmaceuticals reports Q3 results
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$65m |
| Dec 31 2023 | US$2m | US$586k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$4m | US$564k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$72m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$65m |
| Dec 31 2021 | US$4m | US$545k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$50m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$1m | US$495k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$27m |
| Dec 31 2019 | US$628k | US$461k | -US$25m |
Compensation vs Market: David's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD651.40K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Mack (62 yo)
11.4yrs
Tenure
US$2,209,795
Compensation
Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$2.21m | 1.25% $ 953.7k | |
| Co-Founder | 11.9yrs | US$220.27k | 0.79% $ 602.5k | |
| Chief Development Officer | 5.5yrs | US$1.10m | 0.044% $ 33.4k | |
| Chief Financial Officer | less than a year | no data | 0.012% $ 9.1k | |
| General Counsel | 4.3yrs | no data | no data | |
| Senior VP and Head of Corporate Development & Investor Relations | 3.3yrs | no data | no data | |
| Vice President of Human Resources | 1.9yrs | no data | no data | |
| Senior Vice President of Drug Discovery & CMC | no data | no data | no data | |
| Senior VP and Head of Clinical Development & Medical Affairs | 1.6yrs | no data | no data | |
| VP & Head of Clinical Operations | no data | no data | no data |
3.8yrs
Average Tenure
62yo
Average Age
Experienced Management: PMVP's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.5yrs | US$2.21m | 1.25% $ 953.7k | |
| Co-Founder | 11.5yrs | US$220.27k | 0.79% $ 602.5k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.1yrs | US$124.27k | no data | |
| Independent Chairman of the Board of Directors & Member of Scientific Advisory Board | 4.5yrs | US$176.77k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director & Chair of Clinical Advisory Board | 3.7yrs | US$133.27k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.27k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$127.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: PMVP's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:03 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PMV Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Joshua Schimmer | Evercore ISI |